Emboline Secures $20M: Emboliner System Nears Market Launch
March 13, 2026, 9:39 am
Emboline, a Santa Cruz medtech innovator, secured $20 million from Trinity Capital. This growth capital fuels the commercial launch of its Emboliner Embolic Protection System. The device offers crucial protection. It prevents stroke and vital organ damage. It captures debris during complex structural heart procedures like TAVR. This financing follows a successful clinical trial. Emboline plans aggressive regulatory submissions. It targets commercial market entry in the U.S. and Europe this year. This investment solidifies Emboline's mission to redefine patient safety. It promises safer, more confident transcatheter interventions. Emboline delivers groundbreaking solutions for cardiovascular health.
SANTA CRUZ, CA –
SANTA CRUZ, CA – Emboline, a leading medical technology company, announced a significant financial milestone. It secured $20 million in growth capital. Trinity Capital provided the investment. This funding accelerates Emboline's mission. It targets crucial advancements in cardiovascular patient safety.
The capital infusion will propel the commercial launch of Emboline’s flagship product. This is the Emboliner Embolic Protection System. It will also support continued development. The company’s embolic protection technology platform expands. Emboline is based in Santa Cruz, California. It focuses on reducing serious complications. These occur during transcatheter cardiovascular procedures.
A Critical Need for Protection
Structural heart interventions offer life-saving treatment. Yet, they carry inherent risks. Embolic debris can dislodge during these procedures. This debris can travel. It reaches the brain and other vital organs. This migration causes severe events. Stroke and ischemic damage are significant concerns. These complications impact patient outcomes. They also increase healthcare costs.
The Emboliner system addresses this critical challenge. It is designed for comprehensive protection. The system captures and removes debris. This debris might be released during interventions. It provides full cerebral and systemic embolic protection. This means safeguarding the brain. It also protects other essential organs. The Emboliner system aims to make these procedures safer.
Transcatheter Aortic Valve Replacement (TAVR) is one such procedure. TAVR offers a less invasive option for valve replacement. But it carries stroke risk. The Emboliner system is particularly relevant here. It offers cardiologists a vital tool. It boosts confidence during complex procedures. It helps mitigate devastating outcomes. Minimizing embolic complications is paramount.
Strategic Investment Fuels Innovation
Trinity Capital's $20 million investment highlights confidence. It underscores belief in Emboline’s technology. It recognizes market potential. Growth capital is crucial for medtech companies. It bridges development phases to commercialization. This funding allows Emboline to scale operations. It prepares for widespread product adoption. This includes manufacturing and sales infrastructure.
Trinity Capital specializes in life sciences investments. Its support validates Emboline's scientific rigor. It confirms its commercial strategy. This partnership brings more than just capital. It signifies a strategic alignment. Both entities aim to advance medical innovation. This collaboration accelerates the path to market. It benefits patients globally.
Path to Market: Clinical Success and Regulatory Drive
Emboline’s funding comes at a pivotal time. The company recently completed enrollment. This was for its PROTECT H2H clinical trial. This is an investigational device exemption (IDE) study. It prospectively randomized patients. The trial evaluated the Emboliner system's efficacy. Its safety was also assessed. This trial represents a crucial validation step.
Results from the PROTECT H2H trial are anticipated soon. They will be presented at a major medical conference. The American College of Cardiology Annual Scientific Session hosts the reveal. This will occur on March 29, 2026, in New Orleans. These results are expected to bolster Emboliner's market entry. Positive data will underscore its value.
The company is now accelerating regulatory submissions. It targets key global markets. The United States and Europe are primary targets. Emboline aims for commercial launches later this year. The Emboliner device remains investigational for now. It is not yet commercially available. But regulatory pathways are being cleared. This prepares the ground for a rapid market introduction.
CEO Scott Russell leads Emboline. He drives the company's vision forward. His leadership focuses on patient-centric innovation. The company's goal is clear. It provides a comprehensive embolic protection solution. This solution aims to reduce stroke. It minimizes ischemic injury. These benefits apply during transcatheter procedures.
Expanding the Platform, Enhancing Patient Care
The current funding extends beyond the Emboliner system. It supports development of additional technologies. These innovations will further reduce embolic risk. The company is building a robust platform. It addresses various aspects of structural heart procedures. This holistic approach promises ongoing advancements. This includes new device iterations. It also involves expanding indications. Emboline aims to protect more patients. It ensures safer outcomes across a broader spectrum of procedures.
Emboline's commitment to patient safety is paramount. Each new development reinforces this. The company strives for continuous improvement. It seeks to equip interventional cardiologists. They need the best tools available. These tools prevent complications. They ensure optimal patient outcomes. This comprehensive strategy sets Emboline apart. It positions the company as a leader. It drives future innovation in cardiovascular care.
The medical community watches Emboline closely. Its progress offers new hope. It targets patients undergoing complex heart interventions. Reducing stroke is a major public health goal. Emboline’s technology directly contributes to this goal. It empowers physicians. It protects patients. This $20 million investment marks more than a financial transaction. It represents a profound vote of confidence. It signifies tangible progress in cardiovascular medicine.
Emboline is poised for significant impact. It will redefine safety standards. It will enhance the lives of countless patients worldwide. The company’s trajectory is clear. It aims for market leadership. It drives medical innovation. The future of structural heart interventions looks brighter. Emboline is leading the way.
The capital infusion will propel the commercial launch of Emboline’s flagship product. This is the Emboliner Embolic Protection System. It will also support continued development. The company’s embolic protection technology platform expands. Emboline is based in Santa Cruz, California. It focuses on reducing serious complications. These occur during transcatheter cardiovascular procedures.
A Critical Need for Protection
Structural heart interventions offer life-saving treatment. Yet, they carry inherent risks. Embolic debris can dislodge during these procedures. This debris can travel. It reaches the brain and other vital organs. This migration causes severe events. Stroke and ischemic damage are significant concerns. These complications impact patient outcomes. They also increase healthcare costs.
The Emboliner system addresses this critical challenge. It is designed for comprehensive protection. The system captures and removes debris. This debris might be released during interventions. It provides full cerebral and systemic embolic protection. This means safeguarding the brain. It also protects other essential organs. The Emboliner system aims to make these procedures safer.
Transcatheter Aortic Valve Replacement (TAVR) is one such procedure. TAVR offers a less invasive option for valve replacement. But it carries stroke risk. The Emboliner system is particularly relevant here. It offers cardiologists a vital tool. It boosts confidence during complex procedures. It helps mitigate devastating outcomes. Minimizing embolic complications is paramount.
Strategic Investment Fuels Innovation
Trinity Capital's $20 million investment highlights confidence. It underscores belief in Emboline’s technology. It recognizes market potential. Growth capital is crucial for medtech companies. It bridges development phases to commercialization. This funding allows Emboline to scale operations. It prepares for widespread product adoption. This includes manufacturing and sales infrastructure.
Trinity Capital specializes in life sciences investments. Its support validates Emboline's scientific rigor. It confirms its commercial strategy. This partnership brings more than just capital. It signifies a strategic alignment. Both entities aim to advance medical innovation. This collaboration accelerates the path to market. It benefits patients globally.
Path to Market: Clinical Success and Regulatory Drive
Emboline’s funding comes at a pivotal time. The company recently completed enrollment. This was for its PROTECT H2H clinical trial. This is an investigational device exemption (IDE) study. It prospectively randomized patients. The trial evaluated the Emboliner system's efficacy. Its safety was also assessed. This trial represents a crucial validation step.
Results from the PROTECT H2H trial are anticipated soon. They will be presented at a major medical conference. The American College of Cardiology Annual Scientific Session hosts the reveal. This will occur on March 29, 2026, in New Orleans. These results are expected to bolster Emboliner's market entry. Positive data will underscore its value.
The company is now accelerating regulatory submissions. It targets key global markets. The United States and Europe are primary targets. Emboline aims for commercial launches later this year. The Emboliner device remains investigational for now. It is not yet commercially available. But regulatory pathways are being cleared. This prepares the ground for a rapid market introduction.
CEO Scott Russell leads Emboline. He drives the company's vision forward. His leadership focuses on patient-centric innovation. The company's goal is clear. It provides a comprehensive embolic protection solution. This solution aims to reduce stroke. It minimizes ischemic injury. These benefits apply during transcatheter procedures.
Expanding the Platform, Enhancing Patient Care
The current funding extends beyond the Emboliner system. It supports development of additional technologies. These innovations will further reduce embolic risk. The company is building a robust platform. It addresses various aspects of structural heart procedures. This holistic approach promises ongoing advancements. This includes new device iterations. It also involves expanding indications. Emboline aims to protect more patients. It ensures safer outcomes across a broader spectrum of procedures.
Emboline's commitment to patient safety is paramount. Each new development reinforces this. The company strives for continuous improvement. It seeks to equip interventional cardiologists. They need the best tools available. These tools prevent complications. They ensure optimal patient outcomes. This comprehensive strategy sets Emboline apart. It positions the company as a leader. It drives future innovation in cardiovascular care.
The medical community watches Emboline closely. Its progress offers new hope. It targets patients undergoing complex heart interventions. Reducing stroke is a major public health goal. Emboline’s technology directly contributes to this goal. It empowers physicians. It protects patients. This $20 million investment marks more than a financial transaction. It represents a profound vote of confidence. It signifies tangible progress in cardiovascular medicine.
Emboline is poised for significant impact. It will redefine safety standards. It will enhance the lives of countless patients worldwide. The company’s trajectory is clear. It aims for market leadership. It drives medical innovation. The future of structural heart interventions looks brighter. Emboline is leading the way.